What factors drove the changes in Nutex Health's revenue and profit?

What is Nutex Health's gross profit margin?

What is the market's earnings forecast for Nutex Health next quarter?

What is Nutex Health's latest dividend and current dividend yield?

Did Nutex Health beat or miss consensus estimates last quarter?

What does Nutex Health do and what are its main business segments?

What guidance did Nutex Health's management provide for the next earnings period?

What is the revenue and EPS growth rate for Nutex Health year over year?

- **Revenue explosion**: Q2 2025 revenue up 220% YoY to $244M, driven by 350% growth in Hospital Division. Gross margin 51.1% vs. 29.7% YoY.
- **Arbitration success**: 85% win rate in federal arbitration, 75%+ collection rate. $167.7M arbitration revenue (71% of Hospital Division).
- **Buyback & growth**: $25M stock buyback announced; 15 new hospitals in pipeline, 2 opening Q4 2025.
- **Financial strength**: $96.7M cash, 442% YoY operating cash flow growth. Noncash accounting adjustments with no cash impact.
- **Defensive move**: Rebutted short seller claims, emphasizing regulatory compliance and industry-wide arbitration trends.

**【CEO Summary Section】**
- Q2 2025 revenue reached $244 million, a 220% YoY increase, driven by Hospital Division growth (350% YoY). Gross profit margin improved to 51.1%, up from 29.7% in Q2 2024.
- Patient visits rose 10.6% YoY to 45,573, with mature hospitals showing 0.6% QoQ growth. Arbitration revenue contributed 71% of Hospital Division income.
- Defended against a short seller report, emphasizing compliance with No Surprises Act (NSA) and federal arbitration rules. Filed Form 8-K to clarify processes.
- Launched $25M stock buyback program and advanced 15 new hospital projects, targeting high-growth markets.

**【CFO Financial Commentary】**
- Q2 2025 adjusted EBITDA was $73.3 million vs. $6.8 million YoY. Operating cash flow grew 442% YoY to $27.1 million.
- Delays in 10-Q filing due to reclassifying $10-20M stock-based compensation as liabilities; noncash adjustments with no impact on revenue or cash flow.
- Arbitration collection rate 75%+; 85% of submitted claims won. G&A expenses reduced to 5.1% of revenue (14% YoY).
- Cash balance of $96.7M as of June 30, 2025, supporting growth and buybacks.

**【Population Health Division Update】**
- Q2 2025 revenue $7.7M (down 9.2% YoY) but operating income improved to $0.1M vs. -$0.6M YoY. IPA network expanded to 300+ primary care physicians.
- Focused on value-based care and risk-based arrangements, targeting 1-2 new IPAs annually.

**【Clinical Quality & Cost Management】**
- Patient satisfaction >96%, with 4.7/5 Google ratings. Labor costs 14.7% of revenue, lower than industry peers.
- Supply costs optimized via GPOs, reducing spend 3% YoY despite volume growth.

**【Q&A Highlights】**
- Restatement timeline: 60 days to file Q2 10-Q; no material changes to operations.
- Q3 2025 cash flow strong, consistent with prior quarters.
- 2 hospitals set to open in Q4 2025; 4 more in 2026 pipeline.
- EBITDA margin compression due to arbitration costs and new hospital prep expenses.

NUTX

NUTX fundamentals

You can ask Aime